Reference health
Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial
32/32 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 32 checked references that resolve
resolves10.1016/S1473-3099(21)00330-3
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study
resolves10.15585/mmwr.mm7032e3
Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years — COVID-NET, 13 States, February–April 2021
resolves10.1038/s41467-021-26672-3
Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine
resolves10.1016/j.lanepe.2021.100208
Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study
resolves10.7326/L21-0282
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series
resolves10.1056/NEJMc2108861
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
resolves10.1056/NEJMc2111462
Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
resolves10.1136/annrheumdis-2021-221206
Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series
resolves10.1038/s41591-021-01527-y
Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
resolves10.1016/S0140-6736(21)01699-8
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
resolves10.1136/annrheumdis-2020-219498
Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
resolves10.1136/annrheumdis-2021-220418
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
resolves10.1136/annrheumdis-2021-220647
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study
resolves10.1136/annrheumdis-2021-220626
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression
resolves10.1016/S2665-9913(21)00251-4
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study
resolves10.1136/annrheumdis-2021-220781
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity
resolves10.1136/annrheumdis-2021-220408
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response
resolves10.1016/S0140-6736(21)01420-3
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
resolves10.1016/S0140-6736(21)01115-6
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
resolves10.1038/s41591-021-01449-9
Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
resolves10.1089/bio.2018.0032
Usage Data and Scientific Impact of the Prospectively Established Fluid Bioresources at the Hospital-Based MedUni Wien Biobank
resolves10.1016/S0140-6736(21)01694-9
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
resolves10.1016/S2213-2600(21)00357-X
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
resolves10.1136/annrheumdis-2021-220503
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2
resolves10.1016/S2665-9913(21)00212-5
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study
resolves10.1136/annrheumdis-2021-220597
Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
resolves10.1016/S0140-6736(20)32661-1
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
The 3 references without a DOI — listed, not checked
no DOI — not checkedWaning immunity of the BNT162b2 vaccine: A nationwide study from Israel [Internet]
no DOI — not checkedA third vaccine dose substantially improves humoral and cellular SARS-CoV-2 immunity in renal transplant recipients with primary humoral non-response
no DOI — not checkedHeterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1136/annrheumdis-2021-221558"><img src="https://citestamp.com/citestamped/10.1136/annrheumdis-2021-221558/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1136/annrheumdis-2021-221558)